Evidence map›Paper›PMID 26390435›Full record

ArticlePloS one2015

Cold Plasma Inactivation of Bacterial Biofilms and Reduction of Quorum Sensing Regulated Virulence Factors.

Dana Ziuzina, Daniela Boehm, Sonal Patil, P J Cullen, Paula Bourke

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05894096 (Air Cold Atmospheric Pressure Plasma Treatment for Acceleration of Venous Ulcer Healing), which is not on this map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05894096 naactive not recruitingnot on this mapstarted 2023, after this paper: background citation

Air Cold Atmospheric Pressure Plasma Treatment for Acceleration of Venous Ulcer Healing

TypeinterventionalSponsorClinica Universidad de Navarra, Universidad de NavarraRan2023 to 2025Enrolled68ConditionsVenous Leg UlcerArmsCold Atmospheric Plasma Jet Treatment, Alginate Patch
3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 168 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Evaluation of cold atmospheric pressure plasma effects onIranian journal of microbiology · 2025
    Article
  9. Article
  10. Isolation and Characterization of a NovelAntibiotics (Basel, Switzerland) · 2024
    Article
  11. Antibacterial Activity of Phloretin AgainstFoods (Basel, Switzerland) · 2024
    Article
  12. Sublethal Damage Caused by Cold Plasma onFoods (Basel, Switzerland) · 2024
    Article
  13. Review
  14. Article
  15. Article
  16. Cold plasma for enhanced water purification.Sustainable microbiology · 2024
    Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Dana ZiuzinaPlasma Research Group, School of Food Science and Environmental Health, Dublin Institute of Technology, Dublin 1, Ireland.
Daniela BoehmPlasma Research Group, School of Food Science and Environmental Health, Dublin Institute of Technology, Dublin 1, Ireland.
Sonal PatilPlasma Research Group, School of Food Science and Environmental Health, Dublin Institute of Technology, Dublin 1, Ireland.
P J CullenSchool of Chemical Engineering, University of New South Wales, Sydney, Australia.
Paula BourkePlasma Research Group, School of Food Science and Environmental Health, Dublin Institute of Technology, Dublin 1, Ireland.
UNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The main objectives of this work were to investigate the effect of atmospheric cold plasma (ACP) against a range of microbial biofilms commonly implicated in foodborne and healthcare associated human infections and against P. aeruginosa quorum sensing (QS)-regulated virulence factors, such as pyocyanin, elastase (Las B) and biofilm formation capacity post-ACP treatment. The effect of processing factors, namely treatment time and mode of plasma exposure on antimicrobial activity of ACP were also examined. Antibiofilm activity was assessed for E. coli, L. monocytogenes and S. aureus in terms of reduction of culturability and retention of metabolic activity using colony count and XTT assays, respectively. All samples were treated 'inpack' using sealed polypropylene containers with a high voltage dielectric barrier discharge ACP generated at 80 kV for 0, 60, 120 and 300 s and a post treatment storage time of 24 h. According to colony counts, ACP treatment for 60 s reduced populations of E. coli to undetectable levels, whereas 300 s was necessary to significantly reduce populations of L. monocytogenes and S. aureus biofilms. The results obtained from XTT assay indicated possible induction of viable but non culturable state of bacteria. With respect to P. aeruginosa QS-related virulence factors, the production of pyocyanin was significantly inhibited after short treatment times, but reduction of elastase was notable only after 300 s and no reduction in actual biofilm formation was achieved post-ACP treatment. Importantly, reduction of virulence factors was associated with reduction of the cytotoxic effects of the bacterial supernatant on CHO-K1 cells, regardless of mode and duration of treatment. The results of this study point to ACP technology as an effective strategy for inactivation of established biofilms and may play an important role in attenuation of virulence of pathogenic bacteria. Further investigation is warranted to propose direct evidence for the inhibition of QS and mechanisms by which this may occur.

Indexed as

BiofilmsCold TemperaturePlasma GasesQuorum SensingVirulence FactorsAnimalsBacteriaCHO CellsCricetinaeCricetulusMicroscopy, Electron, ScanningPlasma GasesVirulence Factors

Identifiers

PMID26390435
PMCPMC4577073
OpenAlexW1461032306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.